Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Tax Provisions (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Tax Provisions data on record, last reported at $4.2 million in Q3 2025.

  • For Q3 2025, Tax Provisions fell 42.61% year-over-year to $4.2 million; the TTM value through Sep 2025 reached $24.0 million, down 43.03%, while the annual FY2024 figure was $29.7 million, 35.06% down from the prior year.
  • Tax Provisions reached $4.2 million in Q3 2025 per AMPH's latest filing, down from $8.3 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $18.5 million in Q4 2023 and bottomed at $1.2 million in Q1 2021.
  • Average Tax Provisions over 5 years is $7.2 million, with a median of $6.6 million recorded in 2022.
  • Peak YoY movement for Tax Provisions: surged 7560.0% in 2021, then crashed 67.63% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $7.2 million in 2021, then grew by 1.33% to $7.3 million in 2022, then surged by 154.18% to $18.5 million in 2023, then plummeted by 67.63% to $6.0 million in 2024, then crashed by 30.59% to $4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $4.2 million in Q3 2025, $8.3 million in Q2 2025, and $5.6 million in Q1 2025.